Beam Therapeutics presents updated Phase 1/2 BEAM-302 data at ERS 2026
Beam Therapeutics presented updated clinical data from its Phase 1/2 BEAM-302 trial for alpha-1 antitrypsin deficiency at the European Respiratory Society Congress 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.